Fulcrum Therapeutics (FULC) Accumulated Depreciation & Amortization: 2019-2025
Historic Accumulated Depreciation & Amortization for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $15.3 million.
- Fulcrum Therapeutics' Accumulated Depreciation & Amortization rose 10.17% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 10.84%. This contributed to the annual value of $14.3 million for FY2024, which is 11.73% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $15.3 million for Q3 2025, which was up 2.32% from $15.0 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $15.3 million for Q3 2025, and its period low was $6.7 million during Q1 2021.
- In the last 3 years, Fulcrum Therapeutics' Accumulated Depreciation & Amortization had a median value of $13.5 million in 2024 and averaged $13.4 million.
- Data for Fulcrum Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 54.83% (in 2021) over the last 5 years.
- Over the past 5 years, Fulcrum Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $8.3 million in 2021, then grew by 28.94% to $10.7 million in 2022, then increased by 19.68% to $12.8 million in 2023, then climbed by 11.73% to $14.3 million in 2024, then climbed by 10.17% to $15.3 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $15.3 million for Q3 2025, versus $15.0 million for Q2 2025 and $14.6 million for Q1 2025.